Takeda Pharmaceutical Files 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: May 8, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, reporting
TL;DR
Takeda filed a 6-K on 5/8/25, confirming its Tokyo HQ and 20-F reporting.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on May 8, 2025, reporting as a foreign private issuer. The filing indicates Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan. Takeda is required to file annual reports under Form 20-F.
Why It Matters
This filing provides an update on Takeda's status as a foreign private issuer and confirms its reporting obligations with the SEC.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new financial or operational information.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Registrant
- 001-38757 (company) — SEC File Number
- 20250508 (date) — Filing Date
- 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan (location) — Principal Executive Offices
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who is the filer?
The filer is Takeda Pharmaceutical Company Limited.
When was this report filed?
The report was filed on May 8, 2025.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.
Under which form does Takeda file its annual reports?
Takeda files its annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 8, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).